DekaBank Deutsche Girozentrale
BTAI icon

DekaBank Deutsche Girozentrale’s BioXcel Therapeutics BTAI Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$162K – 1197
2020
Q2 		$162K Buy
+200
New +$130K ﹤0.01% 932

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

DekaBank Deutsche Girozentrale's BTAI Position: Q3 2020 in Review

DekaBank Deutsche Girozentrale sold out of BioXcel Therapeutics (BTAI) in Q3 2020, closing a stake of 200 shares — an estimated $162K sold.

DekaBank Deutsche Girozentrale first reported a position in BTAI in Q2 2020 and held it in 1 quarter. The position peaked at $162K in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q3 2020.

  • DekaBank Deutsche Girozentrale reported no remaining BioXcel Therapeutics position as of Q3 2020 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 200 BioXcel Therapeutics shares in Q3 2020, an estimated $162K.
  • DekaBank Deutsche Girozentrale first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's BioXcel Therapeutics position peaked at $162K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2020.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2020, filed 29 Oct 2020.